London, UK, 26 July 2019: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency, announces that the U.S. Food and Drug Administration (FDA) has approved its lead product…Original Article
FDA Approves Accrufer (ferric maltol) for the Treatment of Iron Deficiency in Adults
